文献速递白血病

抗CD22免疫毒素moxetumomab pasudotox治疗儿童急性淋巴细胞白血病的1期研究

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2017-08-09

这项多中心1期研究纳入55例复发/难治性急性淋巴细胞白血病儿童、青少年及年轻成人,确定moxetumomab pasudotox的最大耐受累积剂量为50 µg/kg×6剂,推荐2期剂量为该水平;47例可评估患者客观缓解率32%,包括11例(23%)复合完全缓解,其中5例流式细胞术微小残留病阴性。

要点

  • 最大耐受累积剂量为50 µg/kg×6剂(剂量水平6B),选为推荐2期剂量。
  • 50 µg/kg×10剂组14例中6例发生溶血性尿毒综合征、血栓性微血管病或类HUS事件,超过最大耐受累积剂量。
  • 47例可评估患者客观缓解率32%,复合完全缓解11例(23%),其中5例流式微小残留病阴性。

核心结论

  • moxetumomab pasudotox在复发或难治性儿童急性淋巴细胞白血病中显示可控的安全性和活性证据。

研究设计与样本

  • 多中心1期研究,纳入55例急性淋巴细胞白血病儿童、青少年和年轻成人。
  • moxetumomab pasudotox以30分钟静脉输注给药,剂量5至50 µg/kg,隔日一次,每21天周期给6剂(队列A和B)或10剂(队列C)。
  • 队列B和C接受地塞米松预防毛细血管渗漏综合征。

主要发现

  • 最常见治疗相关不良事件为可逆性体重增加、肝转氨酶升高和低白蛋白血症。
  • 接受30 µg/kg隔日一次共6剂的患者4例中2例发生剂量限制性毛细血管渗漏综合征。
  • 加入地塞米松预防后未再出现剂量限制性毛细血管渗漏综合征。
  • 接受50 µg/kg共10剂的患者14例中6例发生溶血性尿毒综合征、血栓性微血管病或类HUS事件,超过最大耐受累积剂量。
  • 40 µg/kg共10剂扩展组11例中发生2例HUS/TMA/类HUS事件,超过最大耐受累积剂量。

关键数值与推荐

  • 剂量水平6B(即50 µg/kg×6剂)为最大耐受累积剂量,选为推荐2期剂量。
  • 47例可评估患者中客观缓解率为32%,包括11例(23%)复合完全缓解,其中5例经流式细胞术检测微小残留病阴性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Novel therapies are needed to overcome chemotherapy resistance for children with relapsed/refractory acute lymphoblastic leukemia (ALL). Moxetumomab pasudotox is a recombinant anti-CD22 immunotoxin. A multicenter phase 1 study was conducted to determine the maximum-tolerated cumulative dose (MTCD) and evaluate safety, activity, pharmacokinetics, and immunogenicity of moxetumomab pasudotox in children, adolescents, and young adults with ALL (N = 55). Moxetumomab pasudotox was administered as a 30-minute IV infusion at doses of 5 to 50 µg/kg every other day for 6 (cohorts A and B) or 10 (cohort C) doses in 21-day cycles. Cohorts B and C received dexamethasone prophylaxis against capillary leak syndrome (CLS). The most common treatment-related adverse events were reversible weight gain, hepatic transaminase elevation, and hypoalbuminemia. Dose-limiting CLS occurred in 2 of 4 patients receiving 30 µg/kg of moxetumomab pasudotox every other day for 6 doses. Incorporation of dexamethasone prevented further dose-limiting CLS. Six of 14 patients receiving 50 µg/kg of moxetumomab pasudotox for 10 doses developed hemolytic uremic syndrome (HUS), thrombotic microangiopathy (TMA), or HUS-like events, exceeding the MTCD. Treatment expansion at 40 µg/kg for 10 doses (n = 11) exceeded the MTCD because of 2 HUS/TMA/HUS-like events. Dose level 6B (ie, 50 µg/kg × 6 doses) was the MTCD, selected as the recommended phase 2 dose. Among 47 evaluable patients, an objective response rate of 32% was observed, including 11 (23%) composite complete responses, 5 of which were minimal residual disease negative by flow cytometry. Moxetumomab pasudotox showed a manageable safety profile and evidence of activity in relapsed or refractory childhood ALL. This trial was registered at www.clinicaltrials.gov as #NCT00659425.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wayne AS, Shah NN, Bhojwani D, et al. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Blood. 2017. PMID: 28983018. doi:10.1182/blood-2017-02-749101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。